CARIBOU BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.12 USD | -1.85% |
|
-26.39% | -63.00% |
| Jun. 04 | US Equities Markets Close Mixed Monday as US Manufacturing Contracts | MT |
| Jun. 04 | HC Wainwright Adjusts Price Target on Caribou Biosciences to $9 From $24, Maintains Buy Rating | MT |
Financials (USD)
| Sales 2024 * | 11.74M | Sales 2025 * | 12.57M | Capitalization | 191M |
|---|---|---|---|---|---|
| Net income 2024 * | -167M | Net income 2025 * | -218M | EV / Sales 2024 * | 16.3 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 15.2 x |
| P/E ratio 2024 * |
-1.15
x | P/E ratio 2025 * |
-1.02
x | Employees | 158 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.94% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -2.08% | ||
| 1 week | -26.39% | ||
| Current month | -26.39% | ||
| 1 month | -43.77% | ||
| 3 months | -71.12% | ||
| 6 months | -62.87% | ||
| Current year | -63.00% |
1 week
1.75
2.98
1 month
1.753.92
Current year
1.758.33
1 year
1.758.59
3 years
1.7532.65
5 years
1.7532.65
10 years
1.7532.65
| Managers | Title | Age | Since |
|---|---|---|---|
Rachel Haurwitz
FOU | Founder | 37 | 11-10-27 |
Jason O’Byrne
DFI | Director of Finance/CFO | 55 | 21-02-08 |
Steven Kanner
CTO | Chief Tech/Sci/R&D Officer | 65 | 17-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 55 | 21-03-31 | |
Scott Braunstein
BRD | Director/Board Member | 60 | 21-05-31 |
| Director/Board Member | 60 | 21-11-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.97% | 2 M€ | -25.75% | ||
| 0.61% | 14 M€ | -4.50% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 2.12 | -2.08% | 3,698,354 |
| 24-06-04 | 2.165 | +0.93% | 3,725,036 |
| 24-06-03 | 2.145 | -25.52% | 9,304,021 |
| 24-05-31 | 2.88 | +1.05% | 1,468,953 |
| 24-05-30 | 2.85 | -1.04% | 1,551,688 |
Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT
More quotes
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.
Calendar
2024-06-12
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.12
USD
Average target price
16.62
USD
Spread / Average Target
+684.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -63.00% | 191M | |
| +55.70% | 59.34B | |
| +41.08% | 40.24B | |
| -5.39% | 39.88B | |
| -5.56% | 28.55B | |
| +16.46% | 27.26B | |
| -20.56% | 19.23B | |
| +33.03% | 12.61B | |
| +25.85% | 12.28B | |
| +2.72% | 12.49B |
- Stock Market
- Equities
- CRBU Stock
